Next Article in Journal
Mechanofluorochromic Properties of 1,4-Diphenylanthracene Derivatives with Hypsochromic Shift
Next Article in Special Issue
Regioselective C(sp2)-C(sp3) Coupling Mediated by Classical and Rollover Cyclometalation
Previous Article in Journal
Wastewater Characterization: Chemical Oxygen Demand or Total Organic Carbon Content Measurement?
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 29
Issue 2
10.3390/molecules29020406
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Review on the Applications of Selected Metal-Based Complexes on Infectious Diseases

by
Nondumiso P. Dube
1,
Maxwell Thatyana
1,
Ntebogeng S. Mokgalaka-Fleischmann
1,
Ahmed M. Mansour
2,
Vuyelwa J. Tembu
1 and
Amanda-Lee E. Manicum
1,*
1
Department of Chemistry, Tshwane University of Technology, 175 Nelson Mandela Drive, Private Bag X680, Pretoria 0001, South Africa
2
Department of Chemistry, United Arab Emirates University, Al-Ain 15551, United Arab Emirates
*
Author to whom correspondence should be addressed.
Molecules 2024, 29(2), 406; https://doi.org/10.3390/molecules29020406
Submission received: 13 December 2023 / Revised: 5 January 2024 / Accepted: 10 January 2024 / Published: 14 January 2024
(This article belongs to the Special Issue Synthesis, Characterization and Reactivity of Coordination Complexes and Organometallic Compounds)
Browse Figures
Versions Notes

Abstract

:
Fatalities caused by infectious diseases (i.e., diseases caused by parasite, bacteria, and viruses) have become reinstated as a major public health threat globally. Factors such as antimicrobial resistance and viral complications are the key contributors to the death numbers. As a result, new compounds with structural diversity classes are critical for controlling the virulence of pathogens that are multi-drug resistant. Derivatization of bio-active organic molecules with organometallic synthons is a promising strategy for modifying the inherent and enhanced properties of biomolecules. Due to their redox chemistry, bioactivity, and structural diversity, organometallic moieties make excellent candidates for lead structures in drug development. Furthermore, organometallic compounds open an array of potential in therapy that existing organic molecules lack, i.e., their ability to fulfill drug availability and resolve the frequent succumbing of organic molecules to drug resistance. Additionally, metal complexes have the potential towards metal-specific modes of action, preventing bacteria from developing resistance mechanisms. This review’s main contribution is to provide a thorough account of the biological efficacy (in vitro and in vitro) of metal-based complexes against infectious diseases. This resource can also be utilized in conjunction with corresponding journals on metal-based complexes investigated against infectious diseases.

1. Introduction

Over the last three decades, notable advancements and attempts have been made to stop the spread of infectious illnesses worldwide. These initiatives are focused on the ongoing research and cutting-edge breakthroughs in drug discovery, particularly in the pharmaceutical industries and academic institutions [1,2]. Fungi, viruses, bacteria, and parasites cause what is known as infectious diseases, and they are responsible for numerous mortalities worldwide. Infectious diseases can be divided into two categories, namely emerging (new diseases) or re-emerging diseases (infections that are not new but display issues of drug resistance upon reappearing) [3,4]. Although some infectious diseases, such as polio, Guinea worm disease, lymphatic filariasis, etc., are now thought to be curable, others, such as Chagas disease, sleeping sickness, HIV, malaria, tuberculosis (TB), and COVID-19, still pose a threat to people around the world [2,3].
Specific debilitating conditions including COVID-19, sleeping disease, and tuberculosis are briefly detailed to emphasize the significance of developing alternative therapeutic medications for managing infectious diseases. First off, the feared new coronavirus (SARS-CoV) outbreak that causes COVID-19 (with potential for severe respiratory symptoms or death) has sparked an unparalleled global health crisis that the World Health Organization estimated would result in 3 million fatalities by the year 2020 [5,6]. There are no pharmacological treatments that have been shown to be effective, despite the world’s challenges with the coronavirus unchecked proliferation and its significant effects on healthcare. The greatest challenge confronting medicinal chemists and researchers today is the urgent need to find novel, innovative medication candidates to combat SARS-CoV-2 [7].
Second, the Trypanosoma brucei gambiense subspecies accounted for almost 95% of the 992 cases recorded in 2019 and the sleeping disease is still difficult to cure and detect [8]. The major obstacles to treating this condition are the lack of qualified personnel and the limitations of therapeutic approaches. It can be cured with medication if diagnosed early; however, it is fatal if left untreated. Suramin, pentamidine, melarsoprol, and eflornithine are the primary drugs used in Sub-Saharan Africa to treat sleeping sickness [9]. Unfortunately, the current medications have severe side effects and drug resistance, making new treatments for these terrible infections absolutely necessary [10,11,12].
Third, with 1.5 million fatalities in 2018, tuberculosis exceeded HIV/AIDS as the leading infectious disease-related cause of death globally [13,14,15]. The emergence of drug-resistant TB variants has made treatment even more complex and challenging [15,16,17]. Only a few treatments are effective against Mycobacterium bacilli, and current medications are essentially ineffective against extensively drug resistant and multidrug-resistant mycobacterium tuberculosis strains in immune-compromised patients [17]. In order to shorten the duration of treatment, to combat resistant strains without interfering with antiretroviral drugs, and to combat latent bacilli, new drug development techniques must be created [14,17,18].
As was previously stated, microbial/drug resistance and a lack of medications remain major problems in the treatment of infectious disorders [10,19]. It takes very little time for bacteria to become resistant to classes of conventional antibiotics that only include organic derivatives. Most often, resistance has been found shortly after, or even before, the antibiotic was made commercially available for use by humans [20,21]. An appealing method to address the issue of microbial resistance with traditional organic medication candidates is derivatization with metallic fragments (coordination- or organometallic complexes) [20,21]. However, kinetic, and thermodynamic instability, as well as a dearth of logical and systematic structural changes, make coordination complex derivatization problematic [22].
In contrast, organometallic compounds (metal complexes containing at least one metal–carbon bond with unique, remarkable physicochemical properties) are more stable and offer considerable potential with reasonable modification [22]. Therefore, the development of organometallic drugs is a promising strategy in the search for pharmacological remedies for parasitic, viral, and bacterial diseases. In this contribution, the developments in the biological studies of organometallic compound antiparasitic, antibacterial, and antiviral activities are discussed. Additionally, the reported organometallic compounds that were investigated for their antiparasitic, antibacterial, and antiviral properties, and some mechanisms of action, are referenced in this review. The reported data were systematically collected, read, and analyzed from scientific electronic publishers and databases such as Elsevier, ScienceDirect, Scopus, Scifinder, pub Med, and Google Scholar.

1.1. Antiparasitic Agents

Rodríguez Arce et al. [23] evaluated [RuCp(PPh3)2(CTZ)](CF3SO3) 1 (Cp: cyclopentadienyl and CTZ: Clotrimazole) (Figure 1) for its antiparasitic properties against some trypanosomatids. CTZ was introduced in the half-sandwich motif as it is commonly used as an antifungal agent for inhibiting fungi from synthesizing sterols. Compound 1 (IC50 = 0.25 μM) displayed toxicity against Trypanosoma cruzi. The antiparasitic activity of 1 against T. cruzi is sixfold increased after CTZ (IC50 = 1.8 μM) has been complexed to the ‘RuCp(PPh3)’. Additionally, the compound had activity that was around 30 times greater than that of the control substance, Nifurtimox (IC50 = 8.0 μM) [23,24]. Complex 1 interferes with the biosynthetic process used by T. cruzi to turn squalene into squalene oxide. Alternatively, compound 1 showed growth higher inhibitory activity (IC50 = 0.6 μM) in T. bruceibrucei (strain 427) than CTZ (IC50 > 25 μM), generating a dose-dependent antiproliferative impact on the parasites treated for 24 h [23]. Both CTZ and complex 1 were tested for cytotoxicity against a murine macrophage-like cell line (J774) to determine the specificity of their anti-trypanosomal action. Half-sandwich Ru(II) 1 displayed relatively strong selectivity for both parasites (T. cruzi (0.25 ± 0.08 µM) and T. brucei (0.6 ± 0.1 µM)) over mammalian cells (J774 murine macrophages (1.9 ± 0.1 µM). The selectivity index (SI) data for T. brucei show that 1 (SI = 3) is both more potent and more selective than CTZ (SI < 2) [23].
Two complexes of the formula of [M(mpo)(dppf)]PF6 (M = Pd(II) 2 and Pt(II) 3; mpo: pyridine-2-thiolato-1-oxide, and dppf: 1,1′-bis(diphenylphosphino)ferrocene) (Figure 1) were screened for their toxicity against mycobacterium tuberculosis (MTB) and T. cruzi and VERO epithelial cells (selected as the mammalian cell model) [25]. The ferrocene derivative, dppf, was chosen because it frequently displays low cytotoxicity and gives the molecules in the locations where they are introduced enough lipophilicity to pierce cell membranes [10,25,26]. Both square-planar complexes demonstrated 10–20 times selectivity toxicity against MTB and T. cruzi than Nifurtimox, the reference drug (IC50 = 6.0 μM) [25,27]. In fact, the cytotoxicity of 2 and 3 was quite high on T. cruzi (0.64 ± 0.03 µM and 0.28 ± 0.01 µM) and MTB (2.8 ± 0.7 µM and 1.6 ± 0.3 µM), respectively. Complex 3 is more potent than 2 and the sodium salt of mpo ligand (2.42 ± 0.07 µM) [17,25], revealing the importance of the choice of metal ion in drug design. In addition, the two complexes displayed toxicity in the micromolar range against the epimastigote form of the T. cruzi, Dm28c strain. A two- to a five-fold increase of activity was observed for the free Na mpo (IC50 = 1.33 ± 0.08 µM) 2 and 3, respectively [25]. Moreover, the complexes showed about 10–20 times higher activity than Nifurtimox (IC50 = 6.0 μM) [25,27]. Hence the inclusion of the ferrocene moiety (dppf ligand) on the metal complexes improved the selectivity towards the parasite [25].
The in vitro cytotoxicity activity on VERO epithelial cells (ATCCCCL81) was assessed. On these cells, the IC50 values of 2 and 3 are 24 ± 12 and 5 ± 3 µM, respectively, as well as the selectivity index values being stated in µM units. Molecular docking and experimental studies on T. cruzi protein extracts revealed that both 2 and 3 might be acting as effective inhibitors of NADH-fumarate reductase (TcFR) [25].
A concentration-dependent suppression of proliferation was observed when mid-exponential growth phase epimastigotes were incubated with increasing concentrations (0.2–0.7 µM) of 2. The IC50 value (0.30 ± 0.03 µM) [28], determined after 5 days, is nearly twice as low as the IC50 reported for the Dm28c strain [25]. This suggests that type VI CL Brener, which has a different genetic ancestry, is more susceptible than the type I Dm28c strain. The SI value of 2 for the CL Brener strain was 83. The cell uptake values were found to be 12% and 16% when the parasites treated with five and ten concentrations of IC50 value, respectively [28]. After only 24 h of treatment, compound 2 has a trypanocidal impact, shrinking the parasite’s cell body and triggering necrosis, among other alterations in morphology. When compared to the untreated control infected monolayer, the reduction in intracellular amastigotes was more pronounced after 48 h following incubation.
Further studies on compound 3 (60 ± 3 nM) indicated that the Pt(II) complex has promising anti-trypanosomal activity against CL Brener strain compared to that of Nifurtimox (2.8 ± 0.2 µM) [10,19]. In parasites treated with one and ten concentrations of IC50 value, complex 3 uptake reached ~75% and 19%, respectively [10]. This is in contrast with other metal-based antiproliferative compounds such as pyrodach-2 (0.1%), oxaliplatin (1%) or cisplatin (3%) [10,29]. Complex 3 caused necrosis after 24 h of parasite incubation via a substantial reduction of the mitochondrial membrane potential in a way that was dose-dependent [10]. Cell vitality tests on treated parasites showed significant esterase activity. When compound concentration and incubation time were increased, treated epimastigotes showed rounded morphology, flagellum loss, as well as decreased mobility despite having increased metabolic activity. After 48 h of incubation, 3 mM of 3 were sufficient to lower the total amount of amastigotes for each cell by more than 50% [10].
Mosquillo et al. [30] investigated the effect of 2 and 3 on the general transcriptomic process, on T. cruzi, since the compounds showed a preference for connecting with DNA among other macromolecules studied. More modified transcripts (2327 of the 10,785 identified transcripts) were produced by 2 treatment than by 3 treatment (201 of the 10,773 identified transcripts), indicating that 2 has a transcriptome-level mechanism of action. Similar numbers of proteins with differential expressions (342 and 411 for 2 and 3, respectively) were observed. Additionally, transcripts implicated in DNA binding, oxidative defense, transmembrane transport, protein metabolism, and the ergosterol pathways were discovered to be altered by the presence of these complexes [30].
Rodríguez Arce and his co-workers [31], replaced pyridine-2-thiolato-1-oxide with thiosemicarbazone ligands to create two series of Pd(II) and Pt(II) complexes 4 and 5 (Figure 1) that are comparable to the structures of 2 and 3 in their search for novel antileishmanial medications. Compounds 4 and 5 exhibited antiparasitic efficacy against T. cruzi trypomastigotes, blood-stream T. brucei, and mammalian endothelial cells. Platinum(II) complexes were more potent than palladium analogues. Complexes 5b and 5c displayed the largest anti-T. cruzi (0.79 and 0.76 μM) and anti-T. brucei (IC50 = 0.60 μM and 0.52 μM) activities, respectively, among the tested series [31]. In general, the complexes are more potent than Nifurtimox and the free thiosemicarbazone ligands. Coordination of thiosemicarbazone ligands to either Pd(II) or Pt(II) ion reduced toxicity of mammalian cells and increased selectivity towards both parasites. The complexes selectivity indexes for T. cruzi and T. brucei were in the range 2–66 and 32–83, respectively. Complexes 4 and 5 affect the parasite redox metabolism via interaction with DNA. The most active and selective compound in the new series, 5c (Figure 1), also demonstrated no in vivo toxicity in zebrafish embryos in the concentration range of 1–100 µM [31].
Five tricarbonyl Mn(I) complexes with the general formula of [Mn(bpyR,R)(CO)3(X)]PF6 (bpy: 2,2’-bipyridine; R = 4-COOCH3 and H; X = miconazole (MCZ), ketoconazole (KTZ), and clotrimazole (CTZ)) 6–10 (Figure 1) were screened against a variety of parasitic microorganisms and pathogenic bacteria that cause neglected illnesses including sleeping sickness and leishmaniasis [32]. Investigations were made on the antiparasitic activity against Trypanosoma brucei and Leishmania major and antibacterial activity on eight Gram-positive (Staphylococcus epidermidis, Staphylococcus aureus, Enterococcus faecium, and E. faekalis) and Gram-negative (Yersinia pseudotuberculosa, Y. pestis, Pseudomonas aeruginosa, and Escherichia coli) bacterial strains was determined. Compounds 6–10 exhibited no activity against the Gram-negative bacteria except for 8, which displayed moderate MIC values of 10–20 μM on Y. pestis, Y. pseudotuberculosa and E. coli and had a stronger activity than the free MCZ ligand (MIC > 40 μM) [32]. However, they demonstrated low to sub-micromolar MIC values on Gram-positive bacteria, particularly on S. aureus and S. epidermidis with MIC values of 0.625 μM. Complexes 6–10 were more active than the parent antifungal azole drugs. The toxicity of 6–10 is influenced by the nature of the azole drug coordinated to Mn(I) ion. Among the metal complexes, the activity increases with the type of azole ligand in the order KTZ < MCZ < CTZ [32]. The antileishmanial activity of 6–10 was in the 2–5 μM range, but further development was inhibited by comparably high activity on other mammalian cell lines assessed for comparison, resulting in a relatively low selectivity (SI ranges from 1 to 12). Coordination of the azole drugs to Mn(bpyR,R)(CO)3I moiety resulted in an improvement in the antiparasitic activity against T. brucei and L. major. In fact, T. brucei was more susceptible to 6–10 than L. major. Complexes 6–10 exhibited promising anti-trypanosomal activity, especially compound 6, which had the greatest activity, with an IC50 of 0.7 μM and SI > 10 [32].
Lopes et al. [33] examined the activity of five Au(III) complexes 11–15 (Figure 1) in vitro and in vitro. The complexes displayed high aqueous solution stability as well as antiparasitic efficacy toward the Tulahuen LacZ strain. In spleen cells, complex 14 showed modest cytotoxicity, and a selectivity index (SI) of about 30 [34]. In addition, the treatment with 11–15 (IC50 = 0.3 ± 0.06 μM) was more effective against T. cruzi trypomastigotes than benznidazole (IC50 = 0.84 ± 0.29 mM). The trypanocidal efficacy of benznidazole on T. cruzi Y strain intracellular amastigotes, declined with subsequent concentrations (IC50 = 1.84 ± 0.5 μM). In contrast, complexes 11–15, at the same concentration, showed a strong trypanocidal activity at all doses tested (IC50 = 0.64 ± 0.1 μM). Lopes and co-workers noted that 11–15 have the ability to prevent 50% of parasite multiplication at 780 nM, indicating that 11–15 are four times more effective than benznidazole, while having no cytotoxic effects on mammalian cells [33]. In phosphate-buffered saline, complexes 11–15 turned into the neutral form, which lowered parasitemia and tissue parasitism while preventing tissue damage to the heart and liver at 2.8 mg/kg/day. Upon the neutralization of 11–15, during the acute phase of treatment, 100% of the mice received the gold complex. After 150 days of infection, the parasite load in the acutely infected animals who survived was comparable to those animals treated with the standard dose of benznidazole without displaying the latter’s hepatotoxicity [33]. Additionally, it was discovered that interferon-gamma (IFN-γ) levels might be modulated to target a favorable outcome of the disease [33]. This is the first in vivo experimental model of gold organometallic research on Chagas disease that shows promise.
Adams et al. [35] synthesized cyclopalladated thiosemicarbazone complexes by using phosphorus ligands including PTA and aminophosphines. The aforementioned complexes were developed by breaking the bridging Pd–S bonds of tetranuclear complexes that were previously described [36]. The antiplasmodial properties of the cyclopalladated complexes (16–18, Figure 1, Table 1) were tested against two strains of Plasmodium Falciparum, Dd2 (chloroquine- resistant), and NF54 (sensitive to chloroquine), with inhibitory results at low micromolar concentrations [35,37]. Complexes 16–18, exhibited comparable inhibitory action in both strains, with IC50 values between 1.59 and 2.69 μM [35,37]. Since there is promising biological evidence for mononuclear complexes, altering these complexes may increase their activity.

1.2. Antibacterial Agents

Wenzel et al. [38] reported the powerful antibacterial properties of the hetero-tri-organometallic complex 19 (see Figure 2, Table 2). At MIC of 2 µg mL−1 (1.4 µM, Table 2), it prevents the growth of Gram-positive bacteria, including Staphylococcus aureus ATCC 43300 (MRSA) [38]. Complex 19 has 90 times the activity against MRSA than the commercial antibacterial drug amoxicillin (MIC = 48 µg mL−1, 131 µM) and is equivalent to Norfloxacin (MIC = 0.5 µg mL−1, 1.6 µM). A ruthenocene derivative, 20, was slightly less active than 19, with MICs in the range of 4 to 32 µg mL−1. Both complexes have a high interaction with the bacterial membrane, interfering with membrane-related functions like respiration and cell wall biosynthesis, according to studies on their mode of action [38]. In addition, 19 causes oxidative stress in bacteria, but 20 does not. The pharmacological evaluation of the compounds was constrained by the solubility of both complexes in an aqueous solution, which was approximately 25 µg mL−1 [20]. According to Wenzel et al. [38], ferrocene-induced oxidative stress tends to increase antibacterial efficacy but is not the only factor affecting antibiotic activity.
Derivatives 21 and 22, demonstrated powerful antibacterial action, with MIC values in the range of 2–4 µg mL−1 [20]. The mono-metallic derivative 23, which had the organometallic [Re(dpa)(CO)3] as the only residue while phenyl groups replaced both CpMn(CO)3 and ferrocenyl, was discovered to preserve total antibacterial action. It inhibits MRSA development, at a concentration 2 µg mL−1. The activity is equivalent to that of the parent compound 19 as well as the bi-metallic derivatives 21 and 22. According to these findings, neither the ferrocene nor the CpMn(CO)3 moiety is essential, but the presence of the Re[(dpa)(CO)3] moiety is crucial for antibacterial activity [20]. None of the active compounds 19−23, had any activity against Gram-negative Acinetobacter baumannii, Escherichia coli, or Pseudomonas aeruginosa. This may be due to the existence of the outer membrane of Gram-negative bacteria, which prevents many compounds from reaching the cytoplasmic membrane, where compound 19 exerts its activity. However, 21−23, demonstrated considerably more efficient membrane permeabilization ability than 19 [20]. Moreover, all the derivatives displayed higher solubility in culture media than the trimetallic 19, with 23 having the highest solubility.
Frei and co-workers [39] reported two Ru(II) polypyridyl complexes, [Ru(DIP)2(bdt)] (24) and [Ru(dqpCO2Me)(ptpy)]2+ (25), where DIP = 4,7-diphenyl-1,10-phenanthroline; bdt = 1,2-benzenedithiolate; dqpCO2Me = 4-methylcarboxy-2,6-di(quinolin-8-yl)pyridine); and ptpy = 4′-phenyl-2,2′:6′,2″-terpyridine (Figure 3). They were tested for potential antimicrobial photodynamic therapy (aPDT) applications against Gram-positive Staphylococcus aureus and Gram-negative Escherichia coli bacterial strains. At a light dose of 8 J/cm2 (420 nm), both complexes demonstrated significant aPDT activity against S. aureus, resulting in a >6 log10 CFU reduction at 50 μM concentration. However, at the same light dose and concentration, only complex 25 was able to affect the viability of E. coli by >4 log10 CFU reduction (99.99% reduced viability) [39].
Three rhenium bisquinoline complexes (26–28, Figure 3), were developed by Frei et al. [40] for aPDT. The bisquinoline scaffold with a tertiary amine was chosen as the tridentate ligand with either alkyne, amine, or alkyl groups. The antibacterial efficacy of the complexes was tested against Gram-positive (S. aureus ATCC 25923) and Gram-negative (E. coli ATCC 25922) strains, as well as methicillin-resistant S. aureus (MRSA) and colistin resistant E. coli. These tests were conducted under UV-light (365 nm, 3 J cm−2) and in the dark. All the three complexes demonstrated activity against S. aureus, with compounds 26 and 27 showing nanomolar to micromolar MIC values, indicating their ability to inhibit the growth of S. aureus with and without light irradiation. The MIC were 4- to 16-fold lower when exposed to light, demonstrating that all three compounds had increased activity when exposed to light [40]. No activity (up to 64 µg  mL−1) was observed for E. coli, in the absence of light. However, upon light irradiation, compound 26 showed MIC values as low as 5.8 μM (4 μg mL−1), with modest activity also seen for 27 and 28. When exposed to light, the complexes demonstrated light-induced antibiotic activities against drug-resistant S. aureus and E. coli strains, with MIC values ranging between 0.25–8 µg/mL [40]. The researchers examined cytotoxicity of the rhenium complexes against human cells and haemolytic properties. Complex 26 demonstrated the most promising overall activity, exhibiting mild toxicity against human embryonic kidney (HEK293) cells with a CC50 of 59.9 ± 9.2 μM, and no hemolysis up to 300 μM [40]. Interestingly, light exposure was found to enhance the cytotoxicity of these compounds. Following 1 h of irradiation with a UV lamp at 365 nm, 3 J cm−2, the CC50 for 26 decreased to 19.1 ± 5.7 μM. This suggests that complex 26 is generally more toxic against bacteria (13–26 times more effective against S. aureus and 1.5–3 times more effective against E. coli) than against human cells, even with light-irradiation [40]. Furthermore, it appears that 26–28 may possess two modes of activity, one of which is associated with the generation of ROS possibly leading to destabilization of Fe–S clusters and an increase in aminoglycoside uptake [40].
Machado et al. synthesized and characterized two [MIII(mpo)3] complexes, where mpo = pyridine-2-thiolato 1-oxide and M = Ga (29) or Bi (30) (Figure 4) [17]. Both complexes, along with the analogous [FeIII(mpo)3] compound (31), were biologically tested in the standard strain H37Rv ATCC 27,294 (pan-susceptible), as well as in five clinical isolates that are resistant to the conventional first line antituberculosis medications, isoniazid and rifampicin. The compounds demonstrated excellent effectiveness against the resistant and sensitive strains of M. tuberculosis [17]. The four complexes tested in vitro had MICvalues that ranged from 1.06 µM to 3.29 µM (Table 3). The complexes exhibited equivalent or more significant anti-bacillus activity than drugs currently utilized in treatment. The World Health Organization’s recommended medications used in the first phase of basic treatment, include rifampicin (MIC value around 0.49 µM), isoniazid (MIC = 0.18 µM), pyrazinamide (MIC value varied in the range of 48.74–406.14 µM at pH 5.5), and ethambutol (MIC = 2.45 µM) [17,25].
In the in vitro assay, complex 29 was the most potent among the compounds tested, eradicating 90% of the bacteria at 1.06 µM concentration [17]. This value is comparable to Phase II clinical development medications, such as SQ109. With an MIC value of 3.29 µM, complex 30 showed less activity but nevertheless qualifies as a strong candidate for a novel anti-TB drug as it exhibits greater activity than pyrazinamide (48.74 µM) and kanamycin (3.43 µM) [17]. The cytotoxicity of the two most promising metal compounds, 29 and 31 on VERO epithelial cells (ATCC CCL81), was in vitro assayed to gain further insight into their potential. The IC50 values for these cells as well as the selectivity indexes were evaluated: IC50 Vero cells 29 (10.04 µM), 31 (4.61 µM); SI 29 (9.37), 31 (3.03) [17]. Complex 29 was identified as the compound with the most promise for further drug development.
Three mononuclear cyclometalated iridium(III) complexes bearing dithiocarbamate derivatives were synthesized by Mukherjee et al. [42] (see Figure 4). [Ir(2-C6H4py)2(L)] (where 2-C6H4py = 2-phenylpyridine; and L1H = 4-MePipzcdtH, L2H = MorphcdtH, and L3H = 4-BzPipercdtH for 32–34, respectively). These complexes were synthesized from [Ir(2-C6H4py)2Cl]2·1/4CH2Cl2 by substituting the two bridging chlorides with a single dithiocarbamate ligand [42]. The investigation of the complexes’ antibacterial properties against Escherichia coli, Streptococcus pneumoniae, Vibrio cholera, and Bacillus cereus was performed using agar disk diffusion. These cyclometalated iridium(III) complexes interact with CT-DNA to show that they are effective intercalators to CT-DNA with a sufficient number of coordination sites, and the antibacterial studies indicate that all the iridium(III) complexes show stronger activities against four harmful bacteria (V. cholerae, E. coli, S. pneumoniae, and B. cereus) than the free dithiocarbamic acids (LH) [42]. Among these three complexes, 33 possesses the strongest antibacterial activity [42]. The complexes would become more lipophilic and easier to penetrate bacterial cell membranes if the π-electrons over the chelate ring were to delocalize, thereby inhibiting bacteria from growing [42]. The dithiocarbamic acids (HL) and the iridium(III) complexes antibacterial activity are given in Table 4.
Lu et al. [43] synthesized organometallic complexes with the general structure [M(CN)2(N,N’)]+ (M = Ir or Rh) for iridium(III) complexes 35–38 and rhodium(III) complex 39 that are kinetically inert. Complexes 35 and 36 include a 5-amino-1,10-phenanthroline N,N’-ligand, while complexes 37–39 have the bathophenanthrolineN,N’-ligand [43]. Furthermore, complexes 37 and 39 possess 2-phenylpyridine ligands regarding the CN-ligand, whereas complex 35 has the related 2-(p-tolyl)pyridine ligand. In addition, the larger 2-phenylquinoline and 1-isoquinoline CN-ligands, are carried by 36 and 38, respectively, as shown in Figure 4 [43]. Complexes 36 and 39 were synthesized for the first time by Lu et al. [43], whereas complexes 35 [44], 37 [45], and 38 [46] were previously described.
The complexes 35–39 were tested for anti-bacterial activity against four different strains of bacteria (Enterococcus faecalis, Escherichia coli, Staphylococcus aureus, and Klebsiella pneumoniae). With an average inhibition zone of 15 mm, the racemic complex 35 (rac-35) displayed selective anti-bacterial efficacy against S. aureus [43]. The iridium(III) complex 35 suppressed S. aureus growth with MIC and MBC values of 3.60 and 7.19 μM, respectively, demonstrating its strong bactericidal action. This cyclometallated iridium(III) complex, which is used as a direct and specific S. aureus inhibitor, is the first instance of a substitutionally-inert Group 9 organometallic complex [43]. Complexes 36–39 showed limited antibacterial activity [43].
To design potential metal-based therapies for the management of diseases brought on by tuberculosis and trypanosomatids, Rivas et al. [47] synthesized and fully characterized four new ferrocenyl derivatives, 1,1′-bis(dipheny1phosphino) ferrocene hexafluorophosphate compounds [M(Hino)(dppf)](PF6) and [M(Trop)(dppf)](PF6), where M = Pt(II) or Pd(II) (Figure 5). The four complexes and ligands were assessed for their biological activities against T. brucei, M.tuberculosis (MTB) and L. infantum, and on human lung cells and murine macrophages. The complexes have significantly stronger anti-T. brucei activity than that of the free ligands with IC50 values < 5 μM. Additionally, DNA interactions and impacts on T. brucei redox metabolism were investigated and fluorescence measurements suggested that DNA is a likely target of the new compounds.
With IC50 values < 5 μM, the heterobimetallic ferrocenyl complexes significantly increased the anti-T. brucei activity for the free ligands (>28- and >46-fold for Trop (40, 42) and 6- and 22-fold for Hino (41, 43) coordinated to Pt-dppf and Pd-dppf, respectively) [47]. The complexes were more effective than, Nifurtimox. The novel ferrocenyl analogues were more parasite-selective than the free ligands. Pd(II) complexes (42, 43) (IC50 values ranging from 1.2 to 1.3 μM) were slightly more cytotoxic (1.6- to 3.8-fold) against parasites than Pt(II) complexes (40, 41) (IC50 values ranging from 2.1 to 4.5 μM), and all Pd(II) complexes were found to be approximately 10-fold more powerful than Nifurtimox [47]; Nifurtimox (IC50 values: T. brucei= 15 ± 3 μM; murine macrophage = 150 ± 5 μM) [48].
The free ligands, HTrop (IC50 67 μM) and dppf (IC50 45 μM) displayed comparable toxicity against macrophages, while HHino is not toxic even at 100 μM. Independently of the ligand, complexation with [Pd-dppf] enhanced the cytotoxicity of the analogues for the free ligands in the following sequence: complex 43 (>30-fold cytotoxic) > 42(>6.7-fold cytotoxic) [47]. On J774 murine macrophages, the Pt(II) compounds (40, 41) were less toxic than those containing Pd(II) (42, 43), with selectivity index values of up to 23 [47]. All of the synthesized derivatives had anti-leishmanial activity at least two orders of magnitude less potent than that of the reference medication, amphotericin B [47].
The ferrocenyl analogues demonstrated more activity on sensitive MTB compared to the free ligands (MIC90 = 9.88–14.73 μM) and displayed minimal pathogen selectivity [47]. The calculated SI values against the human lung fibroblasts MRC-5 were ≤1. When compared to the sensitive strain (H37Rv), The complexes efficacy against the clinical strains was lower [47]. The HHino ligand, as well as the Pt-dppf and Pd-dppf derivatives (MIC90 = 13.1–35.4 µM) were active against the susceptible strain (H37Rv); however they were ineffective against the resistant variants (MIC90 > 25 µM). The most effective analogues against the triple resistant TB strain CF100 were HTrop (MIC90 = 18.30 μM) and 42 (MIC90 = 9.05 μM), proving their anti-TB potential. The antiparasitic activity cannot be attributed to the complexes interfering with the pathogen thiol-redox homeostasis, according to the mechanism of action [47].
A novel bidentate organometallic Schiff base ligand (L), (2-(1-((2-amino-5-nitrophenyl)imino)ethyl)cyclopenta-2,4-dien-1-yl)(cyclopenta-2,4-dien-1-yl)iron and its Cr(III) (44), Mn(II) (45), Fe(III) (46), Co(II) (47), Zn(II) (48), Cd(II) (49), Ni(II) (50), and Cu(II) (51) complexes (Figure 5), were synthesized by Mahmoud et al. [49]. These were tested for antimicrobial activity against several fungal and bacterial species by utilizing the disc diffusion technique [49]. Complex 49 demonstrated higher activity with an inhibition ratio of 74% against breast cancer and a lower side effect on normal cells than the others, while complex 47, 48, and 49 had higher activities against all various bacterial species than the other complexes [49]. The bacterial organisms used in in vitro antibacterial and antifungal activities were Gram-positive bacteria (Streptococcus mutans, Staphylococcus aureus), Gram-negative bacteria (Klebsiella pneumonia, Pseudomonas aeruginosa, Escherichia coli), and fungal species including (Candida albicans). In comparison, complexes 47–49, demonstrated greater activity against all types of bacterial species (inhibition zone diameter = 10.7–40.7 mm/mg) [49]. Complex 48 was the most active compound against streptococcus mutans species (40.7 ± 0.6 mm/mg), surpassing the Schiff base ligand (24.0 ± 1.0 mm/mg) and ampicillin standard. No activity was shown by 44, 46, and 50 against any species [49]. Candida albicans was biologically inhibited by the Schiff base ligand with 13.30 mm/mg. Compared to the standard antifungal medication (Ketoconazole) and the parent ligand, complex 49 was a more potent fungicide. Complex 49 demonstrated fungicidal activity against the same species at 14.30 mm/mg. The other complexes had no effect on Candida albicans [49].
To enhance the rapidly expanding interest in metal NHC complexes’ biological characteristics, Bernier et al. [50] synthesized a series of IrIII and RhIII piano-stool complexes of the form [(η5-Cp*R)M(NHC)Cl2] (M = Rh, Ir) (see Figure 5). These types of piano-stool complexes constitute appealing antimicrobial candidates because of their strong facile modularity and water solubility, allowing effortless modification to adapt the complexes toward particular biological uses and targets [50,51]. The complexes’ antibacterial properties were investigated against Mycobacterium smegmatis. The majority of the complexes had moderate antimicrobial activity (≤15 μM) to high (≤1 μM) against Gram-positive Mycobacterium smegmatis [50]. Rhodium complexes were discovered to have higher activity than iridium complexes, and by using additional hydrophobic Cp*R and NHC ligands, the activity was increased [50].
There are a few exceptions to this trend, with the iridium Cp* complex exhibiting higher activity with Me2-bimy (60) (MIC = 0.92 μM) and the iridium Cp*phenyl complex with IMe (61) (MIC = 0.45 μM). Additionally, the activity of the rhodium complexes having more hydrophobic NHC ligands (53–56,) was significantly increased and it ranged from 0.46 μM to 1.1 μM, compared to that of IMe (52), which was 4.9 μM [50]. The iridium Cp* complexes followed the same pattern, with the exception of IEt variant (58) (MIC = 31 μM), showing significantly less activity against M. smegmatis than 57 (MIC = 8.1 μM), 59 (MIC = 1.6 μM), and 60 (MIC = 0.92 μM) [50]. Furthermore, the introduction of a phenyl-substituted Cp*R into iridium Cp*R complexes containing the IMe NHC ligand improved the performance of the complexes, as 61 (0.45 μM) was discovered to be significantly more powerful than 57 (8.1 μM) and having the lowest MIC of all the tested complexes [50]. The cytotoxicity tests revealed that 55 is only toxic to Calu-3 cell lines and mammalian Vero E6 at 200-fold higher (92 μM) concentrations than the reported activity against M. smegmatis 0.25 μg/mL (0.46 μM). These results emphasize the potential for noble-metal piano-stool antimicrobial compounds to be developed and tailored using N-heterocyclic carbene and Cp*R moieties.

1.3. Anti-Viral Agents

Five gold organometallics were evaluated as inhibitors of two important therapeutic targets of severe acute respiratory syndrome coronaviruses (SARS-CoV), in a study by Gil-Moles et al. [7]. The effects of the chosen experimental gold metallodrugs were investigated on two appropriate coronavirus targets (spike protein, papain-like protease, PLpro). Complexes 62 [52], 64 [53], and 66 [54] were chosen from prior studies on organometallic gold metallodrugs, whereas the initial reports of 63 and 65 were made by Gil-Moles et al. [7]. The SARS-CoV-2 spike protein interaction with the angiotensin-converting enzyme 2 (ACE2) host receptor was inhibited by the gold metallodrugs, potentially interfering with the viral entry process. The gold complexes 62 to 66 showed good IC50 values in the 16–25 µm range, making them marginally more effective than Chloroquine, the reference drug (IC50 value: 31.9 µm) [7].
SARS-CoV-1 and SARS-CoV-2 papain-like protease (PLpro)—a critical enzyme in viral replication—were effectively inhibited by the gold metallodrugs. The potency of the reference inhibitor Disulfiram was matched by the IC50 values of complexes 62, 63, and 66 against PLpro from SARS-CoV-1, in the range 5–7 µm. Complexes 64 and 65 were less active, having IC50 values of 14 µm [7]. The gold compounds 62, 63, and 66 as well as the reference inhibitor Disulfiram, showed potent inhibitory effect against SARS-CoV-2 PLpro, with IC50 values that were near to 1.0 µm. Notably, 64 and 65 had IC50 values above 50 µm and were inactive against SARS-CoV-2 PLpro. Complexes 64 and 65 with their moderate activity against SARS-CoV-1 PLpro (14.2 ± 0.3 µm and 14.1 ± 2.1 µm, respectively), behaved differently from the other complexes, which were more effective against SARS-CoV-2 PLpro than SARS-CoV-1 enzyme [7]. With an IC50 > 100 µm, benzimidazole was utilized as a negative reference.
Notably, the ability of the inhibitors to remove zinc ions from the enzyme’s labile zinc center correlated with the activity of the complexes against both PLpro enzymes [7]. In SARS-CoV-1 PLpro trials, the most potent inhibitors Disulfiram, 62, 63, and 66 were effective zinc ejectors. The zinc-removing action of the moderate SARS-CoV-1 PLpro inhibitors 64 and 65 were strongly time-dependent. Except for 64 and 65, all compounds were efficient zinc ejectors in the tests using SARS-CoV-2 PLpro [7]. Therefore, gold complexes have the potential to target two important pathways in the coronavirus life cycle [7]. The most potent activity was shown against SARS-CoV-2 PLpro with 62, 63, and 66 [7]. Thus, the compounds are among the first highly effective inhibitors of the target enzyme.
To develop effective antiviral therapies to tackle the devastating SARS-CoV-2, Chuong et al. [55] evaluated noble metal organometallic compounds for the virucidal activity against the viral pathogen. The complexes include four rhodium complexes indicated as complexes 67–70 and are shown in Figure 6. Complexes 67, 69, and 70 include the ligands 1,3-dicyclohexylimidazol-2-ylidene (68), phenylglycinato (69), and dipivaloylmethanato (70). The synthesis of each complex as well as its antimicrobial properties were reported previously [50,56,57,58]. Complex 68 and 70 were found to exhibit direct virucidal action against SARS-CoV-2. In addition, subsequent in vitro tests revealed that complex 70 is the most stable and effective complex, demonstrating that both complexes 68 and 70 exhibit minimal toxicity in Vero E6 Calu-3 cells [55].
The activity of four complexes (Figure 6) was tested to inactivate SARS-CoV-2 directly. Chuong et al. [55] chose these specific complexes because they displayed potent antimycobacterial activity against M. smegmatis [50,56,57,58]. Two complexes, Cp*Rh(1,3-dicyclohexylimidazol-2-ylidene)Cl2 (68) and Cp*Rh(dipivaloylmethanato)Cl (70), demonstrated direct virucidal efficacy against SARS-CoV-2 [55]. Complexes 68 and 70, which exhibited the lowest MICs against M. smegmatis (0.46 µM and 2.19 µM, respectively), displayed the strongest virucidal activity against SARS-CoV-2 and were considerably more virucidal than complex 67 and 69 at all concentrations analyzed (p < 0.0001). Complex 68 decreased plaque formation by about 84% at 10 µg/mL compared to complex 70 which significantly reduced plaque formation by 98% (p = 0.0021). Complexes 68 and 70 reduced SARS-CoV-2 by >99% at concentrations of 25 and 50 µg/mL [55].
Extended incubation periods of up to 3 h resulted in higher virucidal activity. Complexes 67 and 69 were less effective in suppressing SARSCoV-2 plaque formation, and efficacy did not improve as concentration was increased [55]. Following in vitro studies indicates that complex 70 is the most stable and effective complex, with both 68 and 70 demonstrating minimal toxicity in Vero E6 and Calu-3 cells [55]. The findings emphasize the potential antiviral activity of organometallic complexes and encourage further research into their efficacy.

2. Conclusions

The potential for organometallic compounds to cure infectious disorders was proven by the discovery of salvarsan in Ehrlich’s laboratory in the early 1900s, an organo arsenic antimicrobial agent [59]. Even so, only a few organometallic compounds have been used to fight these diseases. To prevent the causative parasites from developing resistance genes and to combat the significant adverse effects of current therapies for these diseases, new therapeutic agents are required. The results presented in this review reinforce the potential and significance of focusing on metal complexes for drug discovery in the battle against infectious diseases that are still inefficiently treated. The organometallic compounds demonstrated suitable biological activities against the different pathogens they were tested on and the mechanisms of action were uncovered.
Recent research has highlighted the significant impact of metal coordination on drug design, showing a marked improvement in the biological activity and expanded medicinal applications of established drugs. Notably, organometallic compounds like Pt-dppf-mpo and gold(III)–thiosemicarbazone have emerged as promising agents with anti-parasitic and anti-chagasic properties, warranting further investigation into their animal toxicity and biodistribution. Moreover, pyridine-2-thiol 1-oxide derivatives have shown promise in treating resistant tuberculosis, indicating potential for the development of new bioactive metal complexes. The encouraging biological data for mononuclear complexes suggest that modifications could enhance their activity. Additionally, Group 9 transition metal complexes are under exploration as therapeutic agents due to their unique geometry and properties, with the [Re(CO)3]+ core presenting a promising structure for antibacterial compound development. The focus should be on developing easily synthesizable derivatives with improved solubility and biological potency while maintaining selectivity over mammalian cells. These recent findings underscore the exciting potential of organometallic compounds in advancing novel therapeutic applications.
Further physiochemical studies of these compounds and a broader knowledge of the mechanism of action of organometallic drugs need to be exploited. One of the shortcomings in these studies is the absence of in vivo data, which are required to determine whether a compound has any genuine pharmacological potential. Limited in vivo studies on these compounds can be attributed to their high reactivity and heavy metal content, which raises concerns about potential toxicity to living organisms, including humans. Moreover, the complex nature of organometallic compounds and their mechanisms of action may not be fully understood, making it difficult to predict their efficacy and potential side effects. Nevertheless, the findings from this study should help open the door for further studies on these promising compounds and on the derivatization of current drugs with organometallic moieties as well as on future designs of new complexes as possible antimicrobial agents with novel mechanisms of action.

Author Contributions

N.P.D. conceptualized, read, reviewed, and wrote the original draft of the manuscript; M.T., N.S.M.-F., A.M.M., V.J.T. and A.-L.E.M. read, reviewed, corrected, and provided insights into the review on the applications of selected metal-based complexes on infectious diseases. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the National Research Foundation, grant number TTK2204295276, and Tshwane University of Technology, Pretoria, South Africa.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Data is openly available and no new data were created for this study.

Conflicts of Interest

The authors declare no conflict of interest. Funders had no role in the design of the study, in the collection, analyses, or interpretation of data, in the writing of the manuscript, or in the decision to publish the results.

References

  1. Bloom, D.E.; Black, S.; Rappuoli, R. Emerging infectious diseases: A proactive approach. Proc. Natl. Acad. Sci. USA 2017, 114, 4055–4059. [Google Scholar] [CrossRef]
  2. Bloom, D.E.; Cadarette, D. Infectious disease threats in the twenty-first century: Strengthening the global response. Front. Immunol. 2019, 10, 549. [Google Scholar] [CrossRef]
  3. Morens, D.M.; Folkers, G.K.; Fauci, A.S. The challenge of emerging and re-emerging infectious diseases. Nature 2004, 430, 242–249. [Google Scholar] [CrossRef]
  4. Sperk, M.; Van Domselaar, R.; Rodriguez, J.E.; Mikaeloff, F.; Sá Vinhas, B.; Saccon, E.; Sonnerborg, A.; Singh, K.; Gupta, S.; Végvári, Á.; et al. Utility of Proteomics in Emerging and Re-Emerging Infectious Diseases Caused by RNA Viruses. J. Proteome Res. 2020, 19, 4259–4274. [Google Scholar] [CrossRef]
  5. WHO. The True Death Toll of COVID-19: Estimating Global Excess Mortality; World Health Organisation: Geneva, Switzerland, 2021; Available online: https://www.who.int/data/stories/the-true-death-toll-of-covid-19-estimating-global-excess-mortality (accessed on 30 August 2021).
  6. Wang, C.; Horby, P.W.; Hayden, F.G.; Gao, G.F. A novel coronavirus outbreak of global health concern. Lancet 2020, 395, 470–473. [Google Scholar] [CrossRef]
  7. Gil-Moles, M.; Basu, U.; Büssing, R.; Hoffmeister, H.; Türck, S.; Varchmin, A.; Ott, I. Gold Metallodrugs to Target Coronavirus Proteins: Inhibitory Effects on the Spike-ACE2 Interaction and on PLpro Protease Activity by Auranofin and Gold Organometallics. Chemistry 2020, 26, 15140–15144. [Google Scholar] [CrossRef]
  8. Kennedy, P.G.; Rodgers, J. Clinical and neuropathogenetic aspects of human African trypanosomiasis. Front. Immunol. 2019, 10, 39. [Google Scholar] [CrossRef]
  9. Cavalli, A.; Bolognesi, M.L. Neglected tropical diseases: Multi-target-directed ligands in the search for novel lead candidates against Trypanosoma and Leishmania. J. Med. Chem. 2009, 52, 7339–7359. [Google Scholar] [CrossRef]
  10. Mosquillo, M.F.; Bilbao, L.; Hernández, F.; Tissot, F.; Gambino, D.; Garat, B.; Pérez-Díaz, L. Trypanosoma cruzi biochemical changes and cell death induced by an organometallic platinum-based compound. Chem. Biol. Drug Des. 2018, 92, 1657–1669. [Google Scholar] [CrossRef]
  11. Zhou, Q.; Hu, H.; Li, Z. New insights into the molecular mechanisms of mitosis and cytokinesis in trypanosomes. Int. Rev. Cell Mol. Biol. 2014, 308, 127–166. [Google Scholar] [CrossRef]
  12. Herwaldt, B.L.; Dougherty, C.P.; Allen, C.K.; Jolly, J.P.; Brown, M.N.; Yu, P.; Yu, Y. Characteristics of patients for whom benznidazole was released through the CDC-sponsored investigational New Drug Program for Treatment of Chagas Disease—United States, 2011–2018. Morb. Mortal. Wkly. Rep. 2018, 67, 803–805. [Google Scholar] [CrossRef] [PubMed]
  13. Harding, E. WHO global progress report on tuberculosis elimination. Lancet Respir. Med. 2020, 8, 19. [Google Scholar] [CrossRef] [PubMed]
  14. Wu, L.; Ye, Z.; Liu, H.; Guo, H.; Lin, J.; Zheng, L.; Chu, N.; Liu, X. Rapid and highly sensitive quantification of the anti-tuberculosis agents isoniazid, ethambutol, pyrazinamide, rifampicin and rifabutin in human plasma by UPLC-MS/MS. J. Pharm. Biomed. Anal. 2020, 180, 113076. [Google Scholar] [CrossRef] [PubMed]
  15. Khawbung, J.L.; Nath, D.; Chakraborty, S. Drug resistant Tuberculosis: A review. Comp. Immunol. Microbiol. Infect. Dis. 2020, 74, 101574. [Google Scholar] [CrossRef] [PubMed]
  16. Miyata, M.; Pavan, F.R.; Sato, D.N.; Marino, L.B.; Hirata, M.H.; Cardoso, R.F.; de Melo, F.A.F.; Zanelli, C.F.; Leite, C.Q.F. Drug resistance in Mycobacterium tuberculosis clinical isolates from Brazil: Phenotypic and genotypic methods. Biomed. Pharmacother. 2011, 65, 456–459. [Google Scholar] [CrossRef] [PubMed]
  17. Machado, I.; Marino, L.B.; Demoro, B.; Echeverría, G.A.; Piro, O.E.; Leite, C.Q.; Pavan, F.R.; Gambino, D. Bioactivity of pyridine-2-thiolato-1-oxide metal complexes: Bi (III), Fe (III) and Ga (III) complexes as potent anti-Mycobacterium tuberculosis prospective agents. Eur. J. Med. Chem. 2014, 87, 267–273. [Google Scholar] [CrossRef]
  18. Orme, I. Tuberculosis Drug Screening Program. Search for new drugs for treatment of tuberculosis. Antimicrob. Agents Chemother. 2001, 45, 1943–1946. [Google Scholar] [CrossRef]
  19. Fernández, M.; Varela, J.; Correia, I.; Birriel, E.; Castiglioni, J.; Moreno, V.; Pessoa, J.C.; Cerecetto, H.; González, M.; Gambino, D. A new series of heterolepticoxidovanadium (IV) compounds with phenanthroline-derived co-ligands: Selective Trypanosoma cruzi growth inhibitors. Dalton Trans. 2013, 42, 11900–11911. [Google Scholar] [CrossRef]
  20. Patra, M.; Wenzel, M.; Prochnow, P.; Pierroz, V.; Gasser, G.; Bandow, J.E.; Metzler-Nolte, N. An organometallic structure-activity relationship study reveals the essential role of a Re (CO)3 moiety in the activity against gram-positive pathogens including MRSA. Chem. Sci. 2015, 6, 214–224. [Google Scholar] [CrossRef]
  21. Patra, M.; Gasser, G.; Metzler-Nolte, N. Small organometallic compounds as antibacterial agents. Dalton Trans. 2012, 41, 6350–6358. [Google Scholar] [CrossRef]
  22. Hartinger, C.G.; Dyson, P.J. Bioorganometallic chemistry—From teaching paradigms to medicinal applications. Chem. Soc. Rev. 2009, 38, 391–401. [Google Scholar] [CrossRef] [PubMed]
  23. Rodríguez Arce, E.; Sarniguet, C.; Moraes, T.S.; Vieites, M.; Tomaz, A.I.; Medeiros, A.; Comini, M.A.; Varela, J.; Cerecetto, H.; González, M.; et al. A new ruthenium cyclopentadienyl azole compound with activity on tumor cell lines and trypanosomatid parasites. J. Coord. Chem. 2015, 68, 2923–2937. [Google Scholar] [CrossRef]
  24. Álvarez, G.; Varela, J.; Márquez, P.; Gabay, M.; Rivas, C.E.A.; Cuchilla, K.; Echeverría, G.A.; Piro, O.E.; Chorilli, M.; Leal, S.M.; et al. Optimization of Antitrypanosomatid Agents: Identification of Nonmutagenic Drug Candidates with in Vivo Activity. J. Med. Chem. 2014, 57, 3984–3999. [Google Scholar] [CrossRef]
  25. Rodríguez Arce, E.; Mosquillo, M.F.; Pérez-Díaz, L.; Echeverría, G.A.; Piro, O.E.; Merlino, A.; Coitiño, E.L.; Ribeiro, C.M.; Leite, C.Q.; Pavan, F.R.; et al. Aromatic amine N-oxide organometallic compounds: Searching for prospective agents against infectious diseases. Dalton Trans. 2015, 44, 14453–14464. [Google Scholar] [CrossRef] [PubMed]
  26. Biot, C.; Dive, D. Bioorganometallic chemistry and malaria. In Medicinal Organometallic Chemistry; Springer: Berlin/Heidelberg, Germany, 2010; Volume 32, pp. 155–193. [Google Scholar]
  27. Gambino, D.; Fernández, M.; Santos, D.; Etcheverría, G.A.; Piro, O.E.; Pavan, F.R.; Leite, C.Q.; Tomaz, I.; Marques, F. Searching for gallium bioactive compounds: Gallium (III) complexes of tridentate salicylaldehyde semicarbazone derivatives. Polyhedron 2011, 30, 1360–1366. [Google Scholar] [CrossRef]
  28. Mosquillo, M.F.; Bilbao, L.; Hernández, F.; Machado, I.; Gambino, D.; Garat, B.; Pérez-Díaz, L. Effect of a new anti-T. cruzi metallic compound based on palladium. Biometals 2018, 31, 961–974. [Google Scholar] [CrossRef] [PubMed]
  29. Corte-Rodríguez, M.; Espina, M.; Sierra, L.M.; Blanco, E.; Ames, T.; Montes-Bayón, M.; Sanz-Medel, A. Quantitative evaluation of cellular uptake, DNA incorporation and adduct formation in cisplatin sensitive and resistant cell lines: Comparison of different Pt-containing drugs. Biochem. Pharmacol. 2015, 98, 69–77. [Google Scholar] [CrossRef]
  30. Mosquillo, M.F.; Smircich, P.; Ciganda, M.; Lima, A.; Gambino, D.; Garat, B.; Pérez-Díaz, L. Comparative high-throughput analysis of the Trypanosoma cruzi response to organometallic compounds. Metallomics 2020, 12, 813–828. [Google Scholar] [CrossRef]
  31. Rodríguez Arce, E.; Putzu, E.; Lapier, M.; Maya, J.D.; Azar, C.O.; Echeverría, G.A.; Piro, O.E.; Medeiros, A.; Sardi, F.; Comini, M.; et al. New heterobimetallic ferrocenyl derivatives are promising antitrypanosomal agents. Dalton Trans. 2019, 48, 7644–7658. [Google Scholar] [CrossRef]
  32. Simpson, P.V.; Nagel, C.; Bruhn, H.; Schatzschneider, U. Antibacterial and Antiparasitic Activity of Manganese(I) Tricarbonyl Complexes with Ketoconazole, Miconazole, and Clotrimazole Ligands. Organometallics 2015, 34, 3809–3815. [Google Scholar] [CrossRef]
  33. Lopes, C.D.; Possato, B.; Gaspari, A.P.S.; Oliveira, R.J.; Abram, U.; Almeida, J.P.; Rocho, F.D.R.; Leitao, A.; Montanari, C.A.; Maia, P.I.; et al. Organometallic gold (III) complex [Au (Hdamp)(L14)]+(L1 = SNS-donating thiosemicarbazone) as a candidate to new formulations against Chagas disease. ACS Infect. Dis. 2019, 5, 1698–1707. [Google Scholar] [CrossRef] [PubMed]
  34. Chatelain, E. Chagas Disease Drug Discovery: Toward a New Era. J. Biomol. Screen. 2015, 20, 22–35. [Google Scholar] [CrossRef] [PubMed]
  35. Adams, M.; de Kock, C.; Smith, P.J.; Chibale, K.; Smith, G.S. Synthesis, characterization and antiplasmodial evaluation of cyclopalladated thiosemicarbazone complexes. J. Organomet. Chem. 2013, 736, 19–26. [Google Scholar] [CrossRef]
  36. Chellan, P.; Land, K.M.; Shokar, A.; Au, A.; An, S.H.; Clavel, C.M.; Dyson, P.J.; Kock, C.D.; Smith, P.J.; Chibale, K.; et al. Exploring the versatility of cycloplatinated thiosemicarbazones as antitumor and antiparasitic agents. Organometallics 2012, 31, 5791–5799. [Google Scholar] [CrossRef]
  37. Baartzes, N.; Stringer, T.; Smith, G.S. Targeting sensitive-strain and resistant-strain malaria parasites through a metal-based approach. In Advances in Bioorganometallic Chemistry; Elsevier: Amsterdam, The Netherlands, 2019; pp. 193–213. ISBN 978-0-12-814197-7. [Google Scholar] [CrossRef]
  38. Wenzel, M.; Patra, M.; Senges, C.H.R.; Ott, I.; Stepanek, J.J.; Pinto, A.; Prochnow, P.; Vuong, C.; Langklotz, S.; Metzler-Nolte, N.; et al. Analysis of the mechanism of action of potent antibacterial hetero-tri-organometallic compounds: A structurally new class of antibiotics. ACS Chem. Biol. 2013, 8, 1442–1450. [Google Scholar] [CrossRef]
  39. Frei, A.; Rubbiani, R.; Tubafard, S.; Blacque, O.; Anstaett, P.; Felgenträger, A.; Maisch, T.; Spiccia, L.; Gasser, G. Synthesis, characterization, and biological evaluation of new Ru (II) polypyridyl photosensitizers for photodynamic therapy. J. Med. Chem. 2014, 57, 7280–7292. [Google Scholar] [CrossRef]
  40. Frei, A.; Amado, M.; Cooper, M.A.; Blaskovich, M.A.T. Light-activated rhenium complexes with dual mode of action against bacteria. Eur. J. Chem. 2020, 26, 2852–2858. [Google Scholar] [CrossRef]
  41. Brennan, P.J.; Young, D.B.; Robertson, B.D.; Andersen, P.; Barry III, C.E.; Britton, W. Introduction: Handbook of Anti-Tuberculosis Agents. Tuberculosis 2008, 88, 85–170. [Google Scholar] [CrossRef]
  42. Mukherjee, T.; Mukherjee, M.; Sen, B.; Banerjee, S.; Hundal, G.; Chattopadhyay, P. Synthesis, characterization, interactions with DNA and bovine serum albumin (BSA), and antibacterial activity of cyclometalated iridium (III) complexes containing dithiocarbamate derivatives. J. Coord. Chem. 2014, 67, 2643–2660. [Google Scholar] [CrossRef]
  43. Lu, L.; Liu, L.J.; Chao, W.C.; Zhong, H.J.; Wang, M.; Chen, X.P.; Lu, J.J.; Li, R.N.; Ma, D.L.; Leung, C.H. Identification of an iridium (III) complex with anti-bacterial and anti-cancer activity. Sci. Rep. 2015, 5, 14544. [Google Scholar] [CrossRef]
  44. Lo, K.K.W.; Chung, C.K.; Lee, T.K.M.; Lui, L.H.; Tsang, K.H.K.; Zhu, N. New luminescent cyclometalated iridium (III) diimine complexes as biological labeling reagents. Inorg. Chem. 2003, 42, 6886–6897. [Google Scholar] [CrossRef] [PubMed]
  45. Goldsmith, J.I.; Hudson, W.R.; Lowry, M.S.; Anderson, T.H.; Bernhard, S. Discovery and high-throughput screening of heteroleptic iridium complexes for photoinduced hydrogen production. J. Am. Chem. Soc. 2005, 127, 7502–7510. [Google Scholar] [CrossRef] [PubMed]
  46. Lu, L.; Chan, D.S.H.; Kwong, D.W.; He, H.Z.; Leung, C.H.; Ma, D.L. Detection of nicking endonuclease activity using a G-quadruplex-selective luminescent switch-on probe. Chem. Sci. 2014, 5, 4561–4568. [Google Scholar] [CrossRef]
  47. Rivas, F.; Medeiros, A.; Arce, E.R.; Comini, M.; Ribeiro, C.M.; Pavan, F.R.; Gambino, D. New heterobimetallic ferrocenyl derivatives: Evaluation of their potential as prospective agents against trypanosomatid parasites and Mycobacterium tuberculosis. J. Inorg. Biochem. 2018, 187, 73–84. [Google Scholar] [CrossRef] [PubMed]
  48. Benítez, D.; Medeiros, A.; Fiestas, L.; Panozzo-Zenere, E.A.; Maiwald, F.; Prousis, K.C.; Roussaki, M.; Calogeropoulou, T.; Detsi, A.; Jaeger, T.; et al. Identification of novel chemical scaffolds inhibiting trypanothione synthetase from pathogenic trypanosomatids. PLoS Neglected Trop. Dis. 2016, 10, e0004617. [Google Scholar] [CrossRef]
  49. Mahmoud, W.H.; Deghadi, R.G.; Mohamed, G.G. Metal complexes of novel Schiff base derived from iron sandwiched organometallic and 4-nitro-1,2-phenylenediamine: Synthesis, characterization, DFT studies, antimicrobial activities and molecular docking. Appl. Organomet. Chem. 2018, 32, e4289. [Google Scholar] [CrossRef]
  50. Bernier, C.M.; DuChane, C.M.; Martinez, J.S.; Falkinham, J.O., III; Merola, J.S. Synthesis, Characterization, and Antimicrobial Activity of RhIII and IrIII N-Heterocyclic Carbene Piano-Stool Complexes. Organometallics 2021, 40, 1670–1681. [Google Scholar] [CrossRef]
  51. Lapasam, A.; Dkhar, L.; Joshi, N.; Poluri, K.M.; Kollipara, M.R. Antimicrobial selectivity of ruthenium, rhodium, and iridium half sandwich complexes containing phenyl hydrazone Schiff base ligands towards B. thuringiensis and P. aeruginosa bacteria. Inorganica Chim. Acta 2019, 484, 255–263. [Google Scholar] [CrossRef]
  52. Rubbiani, R.; Kitanovic, I.; Alborzinia, H.; Can, S.; Kitanovic, A.; Onambele, L.A.; Stefanopoulou, M.; Geldmacher, Y.; Sheldrick, W.S.; Wolber, G.; et al. Benzimidazol-2-ylidene gold (I) complexes are thioredoxin reductase inhibitors with multiple antitumor properties. J. Med. Chem. 2010, 53, 8608–8618. [Google Scholar] [CrossRef]
  53. Rubbiani, R.; Can, S.; Kitanovic, I.; Alborzinia, H.; Stefanopoulou, M.; Kokoschka, M.; Ott, I. Comparative in Vitro Evaluation of N-Heterocyclic Carbene Gold(I) Complexes of the Benzimidazolylidene Type. J. Med. Chem. 2011, 54, 8646–8657. [Google Scholar] [CrossRef]
  54. Andermark, V.; Göke, K.; Kokoschka, M.; El Maaty, M.A.A.; Lum, C.T.; Zou, T.; Sun, R.W.Y.; Aguilo, E.; Oehninger, L.; Rodríguez, L.; et al. Alkynyl gold (I) phosphane complexes: Evaluation of structure–activity-relationships for the phosphane ligands, effects on key signaling proteins and preliminary in-vivo studies with a nanoformulated complex. J. Inorg. Biochem. 2016, 160, 140–148. [Google Scholar] [CrossRef] [PubMed]
  55. Chuong, C.; DuChane, C.M.; Webb, E.M.; Rai, P.; Marano, J.M.; Bernier, C.M.; Merola, J.S.; Weger-Lucarelli, J. Noble Metal Organometallic Complexes Display Antiviral Activity against SARS-CoV-2. Viruses 2021, 13, 980. [Google Scholar] [CrossRef] [PubMed]
  56. Karpin, G.W.; Merola, J.S.; Falkinham, J.O., III. Transition metal–α-amino acid complexes with antibiotic activity against Mycobacterium spp. Agents Chemother. 2013, 57, 3434–3436. [Google Scholar] [CrossRef] [PubMed]
  57. Brown, L.C.; Ressegue, E.; Merola, J.S. Rapid access to derivatized, dimeric, ring-substituted dichloro (cyclopentadienyl) rhodium (III) and iridium (III) complexes. Organometallics 2016, 35, 4014–4022. [Google Scholar] [CrossRef]
  58. DuChane, C.M.; Brown, L.C.; Dozier, V.S.; Merola, J.S. Synthesis, Characterization, and Antimicrobial Activity of RhIII and IrIII β-Diketonato Piano-Stool Compounds. Organometallics 2017, 37, 530–538. [Google Scholar] [CrossRef]
  59. Strebhardt, K.; Ullrich, A. Paul Ehrlich’s magic bullet concept: 100 years of progress. Nat. Rev. Cancer 2008, 8, 473–480. [Google Scholar] [CrossRef]
Molecules 29 00406 g001
Figure 1. Chemical structure of some organometallic complexes with antiparasitic properties.
Figure 1. Chemical structure of some organometallic complexes with antiparasitic properties.
Molecules 29 00406 g001
Molecules 29 00406 g002
Figure 2. Hetero-tri-organometallic compounds FcPNA and RcPNA derivatives.
Figure 2. Hetero-tri-organometallic compounds FcPNA and RcPNA derivatives.
Molecules 29 00406 g002
Molecules 29 00406 g003
Figure 3. Chemical structures of ruthenium(II) polypyridyl complexes and rhenium(I) bisquinoline complexes.
Figure 3. Chemical structures of ruthenium(II) polypyridyl complexes and rhenium(I) bisquinoline complexes.
Molecules 29 00406 g003
Molecules 29 00406 g004
Figure 4. Chemical structure of [MIII(mpo)3] complexes, with M = Ga, Fe or Bi, the corresponding ligands and rhodium(III) or iridium(III) complexes.
Figure 4. Chemical structure of [MIII(mpo)3] complexes, with M = Ga, Fe or Bi, the corresponding ligands and rhodium(III) or iridium(III) complexes.
Molecules 29 00406 g004
Molecules 29 00406 g005
Figure 5. Chemical structures of ferrocenyl derivatives, organometallic Schiff base metal complexes and RhIII and IrIII N-heterocyclic carbene piano-stool complexes.
Figure 5. Chemical structures of ferrocenyl derivatives, organometallic Schiff base metal complexes and RhIII and IrIII N-heterocyclic carbene piano-stool complexes.
Molecules 29 00406 g005
Molecules 29 00406 g006
Figure 6. Chemical structure of gold metallodrugs and pentamethylcyclopentadienyl (Cp*) rhodium piano stool complexes.
Figure 6. Chemical structure of gold metallodrugs and pentamethylcyclopentadienyl (Cp*) rhodium piano stool complexes.
Molecules 29 00406 g006
Table 1. Organometallic complexes in vitro antiparasitic activity against different micro-organisms.
Table 1. Organometallic complexes in vitro antiparasitic activity against different micro-organisms.
CompoundTested Micro-OrganismIC50 Value (μM)Reference
1Trypanosoma cruzi0.25 ± 0.08 [23]
T. bruceibrucei (strain 427)0.6 ± 0.1 [23]
2Mycobacterium tuberculosis (Mtb)2.8 ± 0.7 [25]
T. cruzi, Dm28c strain0.64 ± 0.03 [25]
3Mycobacterium tuberculosis (Mtb)1.6 ± 0.3 [25]
T. cruzi, Dm28c strain0.28 ± 0.01 [25]
4aT. cruzi7.58 ± 0.10 [31]
T. brucei0.90 ± 0.05 [31]
4bT. cruzi1.42 ± 0.02 [31]
T. brucei0.93 ± 0.03 [31]
4cT. cruzi3.6 ± 0.05 [31]
T. brucei0.98 ± 0.06 [31]
4dT. cruzi29.4 ± 2.03 [31]
T. brucei1.56 ± 0.04 [31]
5aT. cruzi3.11 ± 0.05 [31]
T. brucei0.77 ± 0.02 [31]
5bT. cruzi0.79 ± 0.06 [31]
T. brucei0.60 ± 0.03 [31]
5cT. cruzi0.76 ± 0.03 [31]
T. brucei0.52 ± 0.03[31]
5dT. cruzi1.32 ± 0.21 [31]
T. brucei1.01 ± 0.04 [31]
6Leishmania major2.0 ± 0.3 [32]
T. brucei0.7 ± 0.1 [32]
7Leishmania major3.6 ± 2.0 [32]
T. brucei13.2 ± 1.2 [32]
8Leishmania major1.8 ± 0.2 [32]
T. brucei0.4 ± 0.4 [32]
9Leishmania major4.7 ± 0.1 [32]
T. brucei2.1 ± 1.9 [32]
10Leishmania major2.2 ± 0.2 [32]
T. brucei0.5 ± 0.4 [32]
KTZLeishmania major66.0 ± 3.9 [32]
T. brucei20.5 ± 0.4 [32]
MCZLeishmania major42.6 ± 7.4 [32]
T. brucei17.5 ± 0.6 [32]
CTZLeishmania major64.6 ± 2.1 [32]
T. brucei17.4 ± 0.6 [32]
11–15T. cruzi trypomastigotes0.3 ± 0.06 [33]
T. cruzi Y strain0.64 ± 0.1[33]
16P. falciparum strains NF54 (CQS) 1.93 ± 0.04[35]
P. falciparum strains Dd2 (CQR)2.69 ± 0.22[35]
17P. falciparum strains NF54 (CQS) 1.81 ± 0.11[35]
P. falciparum strains Dd2 (CQR)1.73 ± 0.16[35]
18P. falciparum strains NF54 (CQS) 1.76 ± 0.074[35]
P. falciparum strains Dd2 (CQR)1.59 ± 0.053[35]
Table 2. Antibacterial activity of the compounds against Gram-positive bacterial strains (the maximum concentration tested was 512 µg mL−1).
Table 2. Antibacterial activity of the compounds against Gram-positive bacterial strains (the maximum concentration tested was 512 µg mL−1).
CompoundMIC
B. subtilisS. aureus
DSM 20231		S. aureus
ATCC43300 (MRSA)
µg mL−1µMµg mL−1µMµg mL−1µM
1921.421.421.4
20322142.764
214321.521.5
2242.942.921.5
2343.321.621.6
Table 3. MIC values of the mpo compounds against M. tuberculosis H37Rv as compared to MIC values of first- and second-line anti-TB drugs.
Table 3. MIC values of the mpo compounds against M. tuberculosis H37Rv as compared to MIC values of first- and second-line anti-TB drugs.
CompoundMIC Value against M. tuberculosis H37Rv (µM)Reference
291.06[17]
303.29[17]
311.53[17]
Isoniazid0.18[41]
Rifampicin0.49[41]
Pyrazinamide48.74–406.14 a[41]
Ethambutol2.45[41]
a At pH 5.5.
Table 4. Data on the antibacterial activity of 32–34, and free dithiocarbamic acids (LH) (100 μg/mL).
Table 4. Data on the antibacterial activity of 32–34, and free dithiocarbamic acids (LH) (100 μg/mL).
Compound for TreatmentInhibition Zone in mm
B. cereusE. coliS. pneumoniaeV. cholerae
L1H4323
L1H7433
L1H5436
325756
3314131315
349879
Chloramphenicol30192028
DMF0000
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Dube, N.P.; Thatyana, M.; Mokgalaka-Fleischmann, N.S.; Mansour, A.M.; Tembu, V.J.; Manicum, A.-L.E. Review on the Applications of Selected Metal-Based Complexes on Infectious Diseases. Molecules 2024, 29, 406. https://doi.org/10.3390/molecules29020406

AMA Style

Dube NP, Thatyana M, Mokgalaka-Fleischmann NS, Mansour AM, Tembu VJ, Manicum A-LE. Review on the Applications of Selected Metal-Based Complexes on Infectious Diseases. Molecules. 2024; 29(2):406. https://doi.org/10.3390/molecules29020406

Chicago/Turabian Style

Dube, Nondumiso P., Maxwell Thatyana, Ntebogeng S. Mokgalaka-Fleischmann, Ahmed M. Mansour, Vuyelwa J. Tembu, and Amanda-Lee E. Manicum. 2024. "Review on the Applications of Selected Metal-Based Complexes on Infectious Diseases" Molecules 29, no. 2: 406. https://doi.org/10.3390/molecules29020406

Article Metrics

Back to TopTop